Bridging The Gap Between Great Ideas And A Great Life Science Business

Small to mid-sized life science companies are under increasing pressure to successfully convert their intellectual property into commercial value. The smaller pharmaceutical, biotech, and medical device companies very often have less experience, and sometimes no experience, at transforming the science that created the promise of value into a sustainable business. Such transformations are especially difficult for the small life science company because of very limited resources and budget restraints. Regulatory challenges, increased competition and market pressures have a disproportionately higher impact on the small life science company. Add further still the growing demands of globalization and the small company dependency on collaborations and partnerships with larger companies for success and executives can easily feel overwhelmed by risks.

Bridging the gap between value promise and value creation involves the strategic utilization of the right talent engaged in the appropriate processes. With the economic pressures and demands for collaboration with global partners, life science company executives correctly turn to soft ware technology as a means for connecting their intellectual property, projects, operations and deliverables that are all part of the product commercialization process. But the software technology available to small to mid-sized life science companies are either prohibitively expensive requiring complex implementations or are not suitable for current or future regulatory challenges.